OBJECTIVES

This module will address in more depth the challenges (rationale , emotional and logistical) of Risk communication that have been raised in previous modules.

Objectives:

To consider the evolution and social impact of the concept of risk and benefit risk

To explore the understanding of risk perception and uncertainty

To consider challenges in healthcare providers-patients communication

To know the regulatory agencies strategies to address the challenges of risk communication

Evolution of risk communication, risk perception, communication of uncertainty, strategies for improving the communication of risk

MODULE PARTS

1. Risk communication in health: evolution of concepts and social impact of drugs
2. Risk perception. Actual vs perceived and factors influencing perception. Population vs individual risk perception
3. Concept of uncertainty. How to deal with this in risk communication
4. Nature and importance of communication of risk of medicines: accessibility of data, conflict of interest and independent information
5. Regulatory agencies' strategies to address the challenges of risk communication

TRAINER TEAM

Coordinator: Prof Daniel Catalán Matamoros (from Université de Bordeaux)

Expert(s): Christa Naboulet, Dr Paul Benkimoun (from Université de Bordeaux), Dr Catherine De Whalley (from AstraZeneca AB), Dr Anita Conforti (from Università di Verona), Pr Frederic Bouder (from University of Maastricht), Pr William Dab (from Conservatoire National des Arts et Métiers), Dr Peter Mol (from Dutch Medicines evaluation Board), Prof Annalisa Capuano, Dr Cristina Scavone, Dr Annamaria Mascolo (from Università degli Studi della Campania Luigi Vanvitelli), Dr Pietro Dri (from Zadig Communication), Dr Giovanni Tognoni (from Mario Negri Institute for Pharmacological Research), Dr Gregory Busse (from Supernus Pharmaceuticals, Inc.), Dr Gerald Dal Pan (from U.S. Food & Drug Administration).